Potassium — Body Handbook

Food · §331

Potassium

Most adults eat about two-thirds of the potassium their bodies want — a quiet shortfall that nudges blood pressure up, hardens the long road to a stroke, and stacks the odds on a first kidney stone. The fix is cheap and old: more whole-food potassium, less sodium, and for many people a single swap of the table salt for a half-potassium blend. In one rural-Chinese trial of nearly 21,000 adults, that salt swap cut deaths by 12% and strokes by 14% over five years.

Do · Daily Evidence Moderate Chapter Food

This is a longevity move, not a daily-energy one — you won't feel it, your blood pressure will. The shopping list is boring on purpose: potatoes, beans, leafy greens, and a $5 canister of potassium-blended salt that replaces the regular one. The effort is small, the evidence is among the strongest in the catalogue, and the people it most rewards are exactly the people least likely to be told about it: anyone with creeping blood pressure, a history of kidney stones, or a standard Western diet built on bread, deli meat, and packaged food.

Sodium and potassium are a pair. The body uses them to hold the right amount of water in the right places and to set the tone of every artery wall. Eat too much of one and too little of the other, and the system runs at slightly the wrong pressure — for years, then decades.

Potassium does three useful things at once. It tells the kidney to dump extra sodium and the water that comes with it, so blood vessels carry a smaller load. It relaxes the muscle in the artery walls themselves, so the same load fits through more easily. And it pulls citrate into the urine, where the citrate grabs calcium before calcium can find oxalate and start a stone NASEM 2019 Curhan et al. 1997. Three different machines, one mineral.

The reason it works on most adults is not that anyone is dramatically deficient — outright low blood potassium is rare and usually comes from a medication, vomiting, or a feeding-tube reset. The reason is the gap between what the body was tuned for (a diet built on plants, with several thousand milligrams of potassium a day) and what most people actually eat now (bread, processed meat, dairy, and packaged food, which carry plenty of sodium and almost no potassium). The shortfall is not a disease, it's a chronic mismatch.

What the trials actually show

Blood pressure is the easiest piece to test, and the trials have been done. Across dozens of randomised studies, raising potassium intake to guideline levels drops systolic pressure by about three points in healthy adults and closer to seven in people already running high Whelton et al. 1997 Filippini et al. 2020. Seven points is what a starter dose of a blood-pressure pill buys you — except the source is what's on your plate.

The DASH trial took this further. It built an entire eating pattern around potassium-rich foods — fruit, vegetables, beans, low-fat dairy — and compared it against a typical American diet at the same sodium level. The pressure drop was 5.5 points in healthy adults and 11.4 points in adults with hypertension within eight weeks Appel et al. 1997. The follow-up trial showed that cutting sodium and raising potassium stacked — they didn't compete Sacks et al. 2001.

Blood pressure is a stand-in, though. The number readers actually want is whether more potassium keeps people alive. For most of the last twenty years the honest answer was "probably, but no one has run the trial." Then someone did.

Kidney stones are the other body of evidence, and it is large but observational. In two Harvard cohorts — roughly 45,000 men followed for four years and 91,000 women followed for twelve — the people eating the most potassium had between 35% and 51% fewer first stones, after adjusting for fluid intake, calcium, and the rest of the diet Curhan et al. 1993 Curhan et al. 1997. A 2018 evidence review pulled the later cohorts in and found the same direction Newberry et al. 2018. No one has run the head-to-head dietary trial for primary prevention, but the mechanism — urinary citrate binding calcium before it can crystallise — is the same one a urologist uses when prescribing potassium citrate to a patient who already forms stones.

What the shortfall costs over time

The average adult in the US eats around 2,400 to 2,700 milligrams of potassium a day. The body wants closer to 3,400. About one adult in ten clears that bar Cogswell et al. 2012. The gap is not dramatic; that's what makes it expensive.

At the population level, a 1,000-milligram-per-day shortfall sustained across decades looks like the slow climb of resting blood pressure from 118 in your twenties to 142 in your sixties — the kind of trajectory your doctor calls "well, blood pressure goes up with age," and then prescribes the first pill for. It looks like the cousin who has a stroke at 64 instead of 78. It looks like the morning you bend over to tie your shoe and feel a kidney stone for the first time, and then again three years later because half of stone-formers get a second one inside a decade Curhan et al. 1993.

None of those outcomes feel like potassium. They feel like ordinary aging. That's the point: the cost of the shortfall doesn't show up as a diagnosis you can blame on one missing nutrient. It shows up as the version of your life where the actuarial curves run a few percent worse than they had to, and the people around you stop being surprised when bad cardiovascular news arrives.

How to actually do it

Two levers, in order of value. The first is the food. The second is the salt shaker.

The food lever closes most of the gap by itself. Potassium is in plants and in dairy; it is concentrated in a handful of foods that happen to be cheap. A baked potato with the skin runs about 925 milligrams. A medium avocado, 975. A cup of cooked spinach, 840. Half a cup of white beans, 600. A cup of plain yogurt, 380. The banana, perversely, is middling at 420 milligrams — half of a baked potato.

The second lever is the salt swap. Replace the table salt and the cooking salt with a potassium-blended product — sold as NoSalt, Nu-Salt, LoSalt, or Morton Lite Salt. The cleanest blend is roughly three parts regular salt to one part potassium chloride, which adds 400 to 700 milligrams of potassium a day at typical cooking volume while quietly cutting sodium. The 75/25 blend tastes the same to most people. The 50/50 blends are bitter and tend to get returned to the cupboard. This is the swap that was tested in the 21,000-person trial; households kept it up for five years Neal et al. 2021.

The two stack. Food does most of the work; the shaker covers the rest and tilts the sodium-to-potassium ratio without anyone counting milligrams.

Who shouldn't do the salt swap

Healthy kidneys are excellent at dumping extra potassium — there is no documented case of a healthy adult getting in trouble from food potassium. The risk is in people whose kidneys can't keep up, or whose medications block the kidney's ability to excrete it.

For everyone else, the risk window is essentially empty. The salt-substitute trial tracked clinical hyperkalemia carefully and did not find a meaningful signal in the substitute group Neal et al. 2021.

What most guides get wrong

The banana is not the potassium food. Bananas are convenient and visible, and they have ended up as the cultural symbol of the mineral. They are a middle-of-the-pack source. Potatoes, beans, spinach, and avocado all carry more per serving. If the daily target is 3,400 milligrams and a banana delivers 420, the banana plan needs eight bananas. The potato plan needs three potatoes. Plan accordingly.

Muscle cramps are mostly not a potassium problem. The story you have heard — exercise hard, lose potassium in sweat, cramp up, eat banana — does not hold up. Sweat is sodium-heavy and potassium-light. The modern cramp literature has moved toward a neuromuscular-reflex explanation: tired muscle fibres misfire and the signal feeds back, with electrolyte status playing at most a small supporting role Maughan and Shirreffs 2007. Real low-potassium cramps exist, but they come from a medication side-effect or a serious medical event, not from a hot run or a long night. Chasing nocturnal cramps with extra bananas is rarely the fix.

Cutting sodium is not the whole sodium story. The blood-pressure conversation spent two decades pointing at salt; the newer evidence points at the ratio of sodium to potassium. Adding potassium and cutting sodium are not the same intervention, and they are not redundant — DASH-Sodium showed they stack additively Sacks et al. 2001. A diet that is moderately salty but rich in fruit, vegetables, and beans can land in a healthier place than one that is technically low-sodium but built on white bread and packaged food Mente et al. 2014.

Potassium pills are not the same as food potassium. Over-the-counter potassium supplements are legally capped at 99 milligrams per dose precisely because higher single doses irritate the gut and, in rare cases, the heart. Food potassium comes packaged with citrate, magnesium, fibre, and a slow absorption profile that pills can't replicate. If a clinician prescribes potassium citrate for stones or hypokalaemia, that is a different story — but the supplement aisle is not the route.

What changes when you start

The first thing that moves is the number on the cuff, and only the cuff. Within two to four weeks of eating to target — or swapping the salt — systolic blood pressure starts drifting down. If you were already hypertensive, the move is on the order of five to ten points; if you weren't, it's two or three Filippini et al. 2020. You won't feel it. Your doctor will see it at the next visit and adjust your trajectory — and a home blood-pressure monitor will show you the same drift yourself, weeks before the appointment.

Over the next several years, the cardiovascular event curves start to bend. The salt-substitute trial's stroke and mortality curves separated steadily across five years; the longer the intervention ran, the bigger the gap Neal et al. 2021. At the population level, this is the reason a public-health body cares about a nutrient most people have never thought about. At your level, it shows up as the cousin who didn't have the stroke, the neighbour who didn't get the kidney stone — the absence of bad news rather than the presence of good.

Across decades, the eating pattern that delivers the potassium delivers other things too: fibre, magnesium, dietary nitrate, polyphenols. Disentangling potassium from "eat more plants" is a problem for researchers; for the reader, it is the same intervention. The trajectory it buys is not "you feel transformed." It is "you remain the person who can tie their own shoes at 78."

Adjacent topics worth a look:

Sodium intake — the other half of the ratio, and the lever many readers already know about.
The DASH eating pattern — the engineered diet this entry is the nutrient cross-section of.
Magnesium — the third electrolyte commonly low in modern diets, with its own (thinner) cardiovascular story.
Blood-pressure screening — the cheapest measurement that tells you whether any of this matters for you personally.
Kidney stones — if you've had one, the conversation widens to fluid, oxalate, and prescription potassium citrate.

Related in the handbook

Helps

— More potassium and less sodium nudges blood pressure down — a quiet lever in any hypertension plan.
— You won't feel potassium working — your blood pressure will. A home cuff is how you actually see the payoff.
— Low potassium and high salt stack the odds on a first kidney stone; oxalate is just one more lever in the same fight.

— Loading up on potassium or swapping in potassium salt can turn dangerous once kidneys are failing — the same move that helps healthy hearts can stop a weak one.
— It's the sodium-to-potassium ratio that matters, and most people have it backwards.
— Potassium and magnesium travel together — low magnesium makes it hard for your body to hold onto potassium no matter how much you eat.
— Potassium-based salt substitutes are one of the easiest ways to raise potassium intake, with the same kidney caveats.
— Swapping to a potassium-blend salt is the easy win — just check it's still iodized, or you trade one gap for another.

Substance + claimed effects

Potassium (K⁺) is an essential dietary cation, the principal intracellular electrolyte, and the natural counterpart to sodium in vascular tone, renal handling of acid–base balance, and smooth-muscle function. The substance in this entry is the daily intake of potassium from food and, as an alternative, from potassium-enriched table salt ("salt substitutes," typically 25–30% KCl mixed with 70–75% NaCl). Claimed consequences across the catalogue's dimensions: lower blood pressure (especially in salt-sensitive and hypertensive populations), fewer cardiovascular events and lower all-cause mortality, reduced risk of calcium-oxalate kidney stones, and improvement in neuromuscular complaints loosely grouped under "muscle cramps." Authoritative bodies (NASEM, WHO, AHA) recommend 3,400–4,700 mg/day for adults; modern intake in the US and most high-income populations runs 2,300–2,700 mg/day, a chronic shortfall driven by the displacement of unprocessed plant foods by ultra-processed food Cogswell et al. 2012 NASEM 2019 WHO 2012. The entry covers the substance holistically — every meaningful consequence the literature supports.

Evidence by addressing question

Mechanism

Potassium lowers blood pressure through multiple converging pathways. Higher K⁺ intake increases urinary sodium excretion (natriuresis) by suppressing the WNK-SPAK-NCC kinase cascade in the distal nephron, blunting sodium reabsorption; the kidney behaves as if the body is sodium-loaded even when it is not. Potassium also relaxes vascular smooth muscle by hyperpolarising membrane potential through inward-rectifier K⁺ channels and by stimulating Na⁺/K⁺-ATPase, lowering intracellular calcium in arteriolar walls. Endothelial nitric-oxide production rises in response to elevated extracellular K⁺. The net effect is reduced peripheral resistance and natriuresis-driven volume offloading NASEM 2019 Aburto et al. 2013.

For kidney stones, the mechanism runs through urine chemistry: dietary potassium (particularly from fruit and vegetables, which carry organic anions like citrate, malate) raises urinary citrate. Citrate complexes calcium in the tubular lumen and inhibits calcium-oxalate crystal nucleation and aggregation. Higher K⁺ intake also lowers urinary calcium excretion — the opposite effect to sodium Curhan et al. 1993 Curhan et al. 1997.

For muscle cramps, the mechanistic story is weaker. Severe hypokalaemia (serum K⁺ < 3.0 mmol/L, almost always from diuretic use, vomiting, or refeeding) produces real cramps and weakness via altered muscle-cell repolarisation. But idiopathic exercise-associated or nocturnal cramps in the general population correlate poorly with serum or whole-body potassium status — neuromuscular reflex theories now dominate the cramp literature Maughan and Shirreffs 2007.

Evidence

Blood pressure. Whelton et al.'s 1997 JAMA meta-analysis of 33 randomised trials (n≈2,600) found oral potassium supplementation reduced systolic BP by ~3.1 mmHg and diastolic by ~2.0 mmHg overall, with larger effects in hypertensive subjects (-4.4 / -2.5 mmHg) Whelton et al. 1997. Aburto's 2013 BMJ systematic review confirmed the pattern across newer trials, with the largest effects again concentrated in adults with hypertension and in those with high baseline sodium intake Aburto et al. 2013. Filippini's 2020 dose-response meta-analysis of 32 RCTs found systolic BP reductions of ~6.8 mmHg in hypertensives at intakes around 3,500 mg/day — a clinically meaningful drop on the same order as a single antihypertensive medication Filippini et al. 2020.

The DASH trial (n=459) showed a dietary pattern high in fruit, vegetables, low-fat dairy, and potassium (~4,700 mg/day) lowered systolic BP by 5.5 mmHg compared with a control diet at the same sodium intake; in hypertensives the effect was 11.4 mmHg Appel et al. 1997. DASH-Sodium (n=412) further showed potassium-rich eating and sodium reduction stack — combined intervention lowered BP by 8.9 mmHg in hypertensives versus the high-sodium control Sacks et al. 2001.

Cardiovascular events and mortality. The Salt Substitute and Stroke Study (SSaSS, n=20,995) is the landmark RCT: rural Chinese adults at high cardiovascular risk were randomised to 75% NaCl / 25% KCl salt vs regular salt, used at home for cooking. Over 4.7 years, the salt-substitute group had 14% fewer strokes (RR 0.86), 13% fewer major cardiovascular events (RR 0.87), and 12% lower all-cause mortality (RR 0.88) Neal et al. 2021. A 2022 meta-analysis of salt-substitute trials (n≈24,000) replicated the directionality across populations Yin et al. 2022. Observational data from NHANES (n=12,267) showed the highest sodium-to-potassium ratio quartile carried roughly double the cardiovascular mortality of the lowest Yang et al. 2011. The PURE study (n=102,216) found higher urinary potassium associated with lower BP and lower stroke risk across 18 countries Mente et al. 2014.

Kidney stones. Two Curhan cohort studies (Health Professionals Follow-up Study, n=45,619 men; Nurses' Health Study, n=91,731 women) found the highest potassium-intake quintile had 35–51% lower risk of symptomatic kidney stones over 4–12 years of follow-up. Effect held after adjustment for fluid intake and dietary calcium Curhan et al. 1993 Curhan et al. 1997. AHRQ's 2018 evidence review aggregated this with later cohorts and confirmed the inverse association Newberry et al. 2018. Mechanism (urinary citrate) is consistent across trials of potassium citrate as a treatment for recurrent stone-formers.

Muscle cramps. Direct trial evidence is thin. The Maughan and Shirreffs review of exercise-associated cramps found no consistent association between potassium status (serum, sweat losses, dietary intake) and cramp incidence in athletes — neuromuscular theories outperform electrolyte-deficit models in the modern literature Maughan and Shirreffs 2007. Anecdotal community reports of "banana for cramps" appear to confound potassium with hydration and with magnesium status (which has its own thin trial base) Schwalfenberg and Genuis 2017.

Protocol

NASEM 2019 set Adequate Intake at 3,400 mg/day (men) and 2,600 mg/day (women), reframed from the previous 4,700 mg "DRI for chronic disease risk reduction" — the change reflects methodological caution about establishing a single intake number for cardiovascular benefit, not a softening of the directional evidence NASEM 2019. WHO maintains a population recommendation of ≥3,510 mg/day for adults WHO 2012. The AHA endorses 3,500–5,000 mg/day for adults with elevated BP Whelton et al. 2018. US median intake sits around 2,400–2,700 mg/day; the >3,400 mg threshold is met by roughly 10–15% of US adults Cogswell et al. 2012 USDA 2020.

Food sources and approximate K⁺ per typical serving: white potato with skin (~925 mg / medium), sweet potato (~540 mg), white beans (~600 mg / ½ cup), lentils (~370 mg / ½ cup), spinach cooked (~840 mg / cup), avocado (~975 mg / whole), banana (~420 mg), tomato (~290 mg / medium), salmon (~530 mg / 4 oz), yogurt plain (~380 mg / cup), orange juice (~470 mg / cup), prune juice (~700 mg / cup). Two of these eaten thoughtfully — say, a baked potato at lunch and a cup of cooked beans at dinner — clear most of the day's gap.

The cleanest engineered intervention is salt substitution: replacing the table-salt shaker and cooking salt with a 25% KCl / 75% NaCl product (NoSalt, Nu-Salt, LoSalt, Morton Lite Salt) adds roughly 400–700 mg potassium per day at typical Western cooking volume while modestly cutting sodium. This was the SSaSS intervention; the trial reported the change was sustainable in households over five years Neal et al. 2021.

Contraindications

The kidneys excrete excess potassium readily in healthy adults, and dietary potassium has not produced documented hyperkalaemia in the absence of impaired excretion. The clinically meaningful contraindications are:

Chronic kidney disease (eGFR < 45–60 mL/min/1.73 m²): impaired potassium excretion makes high intake dangerous. Salt substitutes are explicitly contraindicated by FDA labelling for CKD patients NASEM 2019.
RAAS-blocking medications — ACE inhibitors, ARBs, aldosterone antagonists (spironolactone, eplerenone) — and the potassium-sparing diuretic amiloride: all reduce renal potassium excretion. Combining with high dietary K⁺ or a salt substitute requires monitoring of serum K⁺; this is the population most likely to be told to avoid salt substitutes.
Type 1 diabetes, Addison's disease, severe heart failure: impaired potassium handling at the hormonal level.
NSAIDs in combination with the above: reduce renal blood flow and compound the risk.

SSaSS excluded patients on potassium-sparing diuretics; even so, the trial did not detect a signal for clinical hyperkalaemia events in the substitute arm Neal et al. 2021. Reasonable-population estimate: roughly 10–15% of adults have one of the above conditions and should ask a clinician before adopting a salt substitute, though increasing whole-food potassium remains safer at any single-food level than the concentrated KCl dose in a salt substitute.

Misconceptions

"Bananas are the potassium food." A banana has ~420 mg — middling. A baked potato carries twice that. Spinach, beans, avocado, and yogurt are denser sources per typical serving.
"Sweat cramps mean low potassium." Sweat is sodium-rich and potassium-poor; the cramp story for exercise is mostly neuromuscular and partially sodium/hydration Maughan and Shirreffs 2007.
"Cut sodium, problem solved." Sodium reduction works, but the population-level evidence (SSaSS, PURE) increasingly points at the Na/K ratio rather than either nutrient in isolation. Adding potassium and reducing sodium stack additively Mente et al. 2014 Sacks et al. 2001.
"Potassium supplements equal food potassium." Over-the-counter potassium tablets are capped at 99 mg per dose by the FDA precisely because of GI and arrhythmia risk at higher single doses. Food spreads the load and brings co-nutrients (citrate, magnesium, fibre).

Stakes

The typical reader: a healthy adult with rising or borderline blood pressure, eating a normal Western diet centred on bread, processed meat, dairy, and packaged convenience foods. Their potassium intake is 2,000–2,700 mg/day, two-thirds of guideline. The dossier evidence makes this a slow-burn cardiovascular trajectory: SSaSS demonstrated that a single nutrient swap moved all-cause mortality by ~12% over five years in adults with existing risk Neal et al. 2021. The mechanism (vascular tone, sodium handling, urine chemistry) operates continuously across decades, so the loss is not a discrete event — it is the slow upward drift of BP, the higher lifetime stroke probability, and the accumulating odds on a first kidney stone. Stones recur in 50% of stone-formers within 10 years Curhan et al. 1993.

Payoff

BP drops within ~2–4 weeks of sustained intake change — the trial half-life is short Filippini et al. 2020. The cardiovascular-event reduction (stroke, MI) accumulates over years; SSaSS's curves diverged steadily across five years of follow-up Neal et al. 2021. Kidney-stone risk reduction is a long-cohort outcome — Curhan's effect emerged across 4-year (men) and 12-year (women) follow-ups Curhan et al. 1993 Curhan et al. 1997. Day-to-day felt change is mostly absent in normotensive adults: this is a longevity-tier intervention, not an energy-tier one.

Failure modes

The salt substitute is bought but not used. Many adults try a salt substitute, taste the bitterness of KCl, and revert to NaCl. The 75/25 blend is detectable; the 50/50 blend is unpleasant for most palates.
Adding potassium without removing the source of low intake. Sprinkling a salt substitute over a diet of ultra-processed food adds 400–700 mg but leaves the bigger lever (the missing 3 cups of fruit/vegetables/legumes) untouched. The dietary-pattern intervention (DASH) outperforms isolated potassium dosing for this reason.
Misinterpreting cramps. A reader chasing nocturnal cramps with bananas will not be helped; the fix is rarely dietary potassium.
CKD patients self-prescribing. The single most dangerous failure mode: a salt substitute in someone with undiagnosed early CKD can produce frank hyperkalaemia and arrhythmia.

Practicalities

Cost: produce and legumes are the cheapest sources per gram of potassium delivered. A 1.5 lb bag of dry beans (~$3) at typical use gives ~30 g of potassium across the bag — about a month's gap. A canister of NoSalt or Morton Lite Salt runs $3–6 and lasts months. The intervention sits at the cheap end of the catalogue. Effort is modest — substituting one whole-food side dish per meal and swapping the salt shaker.

The credibility range

Optimist case

Potassium intake is one of the few nutrient-level interventions with a large randomised trial showing reduced all-cause mortality (SSaSS) — a bar most "longevity" interventions in the catalogue fail to clear. Mechanism is well-mapped, dose-response is documented across populations, the intervention is cheap, safe in healthy kidneys, and an authoritative consensus (WHO, AHA, NASEM directionally, FDA salt-substitute permission, the DASH framework) backs it. The Na/K ratio framing reconciles the historical sodium-reduction debate (PURE-style critiques of sodium dose-response) with the durable cardiovascular signal. Population-level potassium increase by 1,000 mg/day could plausibly prevent >150,000 cardiovascular deaths annually in the US alone — the most underused public-health lever of its tier.

Skeptic case

NASEM's 2019 decision to drop the chronic-disease-prevention intake target reflected real concern about the strength of single-threshold evidence: the trials are heterogeneous, intake assessment by recall is noisy, and many BP trials use potassium chloride or bicarbonate salts at doses that don't replicate food intake. SSaSS was conducted in a high-cardiovascular-risk Chinese rural population with notably high baseline sodium and prevalent untreated hypertension — generalisability to a 35-year-old normotensive Western reader is debatable O'Donnell et al. 2020. The kidney-stone effect is observational (no RCT directly tests dietary potassium for primary stone prevention). The muscle-cramp claim is largely folklore. And the headline mortality numbers in observational work are vulnerable to healthy-user confounding — people who eat more fruit and vegetables differ on many dimensions.

Author's call

Lands firmly on the optimist side for blood pressure, cardiovascular events, and kidney stones — the SSaSS RCT plus the meta-analytic dose-response data plus the converging mechanism plus the population shortfall make this one of the better-supported single-nutrient interventions in the catalogue. The muscle-cramp claim, by contrast, is overplayed by popular health media and is not supported by the contemporary literature; the entry will say so. Controversy is low-moderate: the headline "more potassium is good for most people" is consensus; the precise dose target is contested (which is why NASEM softened its number) and the salt-substitution intervention requires the CKD caveat to be applied properly. Evidence rates a 4 — multiple high-quality trials including a definitive mortality RCT, with the headline conclusion replicating across study types; not a 5 because the dose-response in well-nourished normotensive Western readers is less directly established.

Stakeholder + incentive map

Public-health bodies (WHO, AHA, NASEM): push higher potassium intake; aligned with population cardiovascular goals. NASEM has been more methodologically conservative on dose targets than WHO.
Salt-substitute manufacturers (Morton, NoSalt, LoSalt): commercial interest in salt-substitute adoption. Products are old, off-patent, low-margin.
Food industry: ultra-processed food incentives have driven sodium up and potassium down. Reformulation has been slow.
Nephrology / cardiology: generally pro-potassium for healthy patients, cautious for CKD and RAAS-treated patients. The CKD population is the constituency for the "be careful with salt substitutes" message.
Sports / wellness influencer culture: over-attributes cramps and "electrolyte deficits" to potassium; market for electrolyte powders capitalises on this.
Sodium-skeptic camp (PURE investigators, low-sodium critics): less hostile to potassium messaging than to sodium-reduction messaging — the Na/K ratio framing is compatible with both camps.

Population variability

Hypertensives get the largest BP effect (-6 to -8 mmHg systolic at adequate intake), versus ~-2 mmHg in normotensives Filippini et al. 2020.
Salt-sensitive subgroups (African-ancestry adults, older adults, those with existing hypertension or insulin resistance): larger effect from potassium increase and from sodium-potassium ratio improvement.
Calcium-oxalate stone formers: largest absolute benefit from potassium-rich eating; clinical practice for recurrent stone-formers includes potassium citrate prescription.
Athletes: sweat losses are negligible for potassium relative to sodium; supplementation is not warranted by mechanism.
CKD and RAAS-medication users: reduced or no benefit, increased risk; need clinician guidance.
Pregnancy / lactation: AI is slightly higher (2,900 / 2,800 mg) but the same food-source guidance applies.
Vegetarians and DASH-pattern eaters: often already at or above target — entry is most relevant to the standard Western-diet eater.

Knowledge gaps

No large RCT in low-cardiovascular-risk Western populations to confirm SSaSS generalises directly.
No direct RCT of dietary potassium (versus pharmacological potassium citrate) for primary kidney-stone prevention.
Precise dose-response shape in normotensive adults is uncertain; whether the benefit plateaus at 3,400 mg or continues climbing to 4,700 mg is open.
The independent contribution of potassium versus the broader fruit-vegetable-legume pattern (fibre, magnesium, polyphenols, dietary nitrate from leafy greens) is hard to isolate — the DASH effect is potassium-rich but is not a pure potassium intervention.
Real-world adherence and CKD-screening protocols for population-level salt substitution remain unsettled outside of the SSaSS Chinese context.

Brief vs scope. The brief named five consequences (blood pressure, cardiovascular events, kidney stones, muscle cramps, modern-diet shortfall). The article covers all five end-to-end, including the muscle-cramp claim explicitly — the contemporary literature does not support it, so it is handled in misconceptions rather than as a positive consequence. No quiet drop.

Score calls worth noting.

Longevity = 4, not 5. SSaSS is the only mortality RCT and it was conducted in a high-risk rural Chinese cohort with high baseline sodium and prevalent untreated hypertension. The mechanism + dose-response data extrapolates to Western adults, but the direct trial doesn't. Reserving 5 for interventions with replicated mortality RCTs in the catalogue's target population.
Health (short-term) = 1, not 2. The BP drop is real and reasonably fast, but it's silent for almost all readers. Hypertensives might notice; normotensives won't. Score reflects the felt-experience reality, not the biomarker change.
Evidence = 4, not 5. The direction is consensus and trial-backed; the precise daily target is genuinely contested (NASEM 2019 dropped the 4,700 mg chronic-disease threshold). Felt dishonest to claim 5 when the field has just walked back the headline number.
Beauty (cumulative) = 0. Considered scoring 1 (downstream aging benefit via cardiovascular health), but the mechanism is non-cutaneous and the article does not surface a beauty-specific paragraph. The score-and-body-track-each-other rule from the meta spec §5a step 7 made 0 the honest call — better to drop the dimension than to add a thin aesthetic paragraph that would not earn its place.

Contraindications token choice. Used kidney-disease. The full clinical caveat is broader (RAAS-blocking medications, K-sparing diuretics, type 1 diabetes, Addison's, significant heart failure) but the closed token set doesn't cover those cleanly. The article's warning callout handles the medication side; the meta contraindication covers the population most at risk of frank harm. cardiac-condition was considered for severe heart failure but felt too broad — would over-scope.

Future-link candidates. Once these exist, link from the out-of-scope section: sodium, dash-diet, magnesium, blood-pressure-screening, kidney-stones (if a separate condition entry is written).

Separate-entry candidate. Salt substitutes (the SSaSS-style intervention specifically) could warrant their own entry if the catalogue ever wants to cover the public-health policy angle — sodium reformulation, FDA labelling, the population-level RCT history — separately from the nutrient story.

Anchored on the typical reader. Stakes and payoff written for a normotensive-to-mildly-hypertensive adult eating a standard Western diet — not for the salt-sensitive hypertensive on three meds, who has a different conversation with their clinician. The protocol covers both because the food lever is the same.

Citations the article doesn't use but the dossier does. Bernabe-Ortiz 2020 (Peru salt-substitute community trial), Schwingshackl 2017 (food-group meta-analysis), Yang 2011 (NHANES Na/K mortality), Schwalfenberg 2017 (magnesium context for cramp myth), O'Donnell 2020 (sodium-skeptic position), USDA 2020, WHO 2012. Kept in research for the credibility-range work and the population-variability section.